Is Ocular Therapeutix, Inc. (OCUL) halal? Halal. Based on AAOIFI screening, Ocular Therapeutix, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 81/100 (Grade: A).
OCUL โ Is Ocular Therapeutix, Inc. Halal?
HalalOcular Therapeutix, Inc.
$8.31
-6.94%
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Sector: Healthcare ยท Industry: Biotechnology
Shariah Compliance Status
Based on AAOIFI screening standards
Very Good
Strong compliance across all metrics
Business Activity Screen
PassedChecks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)
Financial Ratio Screen
PassedFinancial ratios must be below AAOIFI thresholds
Compliance History
Halalnow
since Jun 2026
Not Halal
until the change above
Tracked since May 2026. Updates automatically on each re-screen.
Purify Your OCUL Dividends
0.1% non-compliant incomeOCUL has 0.1% prohibited income. Calculate exactly how much of your dividends to donate.
Financial Overview
Market Cap
1.8B
Price
$8.31
Sector
Healthcare
Industry
Biotechnology
More Healthcare Stocks
Track OCUL and 10,000+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.